Bristol Myers Squibb will merge its research and development organizations under a single leader, Chief Medical Officer Cristian Massacesi, effective January 1, 2027. The company announced the decision on Thursday and said it will not announce job cuts or pipeline changes alongside the restructuring — a claim worth watching, given BMS's recent headcount trajectory.

Massacesi, an executive vice president who currently also serves as head of development, will lead one organization spanning discovery through development. Robert Plenge, executive vice president and chief research officer, will remain with the company in an advisory role through March 2027 to support the transition. He will then leave, the company confirmed.

What does the merger change for BMS?

CEO Christopher Boerner framed the restructuring as a strategic decision, not a cost exercise. "Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," Boerner said in a statement. He argued the structure will bring scientific and clinical know-how closer together, quicken decisions and strengthen portfolio execution. Boerner also said the lines that once divided research from development are fading across the industry.

Massacesi offered a similar rationale. He said in a statement that uniting the teams will help turn discoveries into medicines with greater speed and focus. Plenge, for his part, said he and Massacesi developed the structure together and that he is confident it is the right path for the company and its patients. Whether that confidence survives the integration's first friction points remains an open question the statements do not address.

What is not being said

The announcement contains no figures on cost savings, no timeline for integration milestones and no detail on how leadership layers below Massacesi will be structured. BMS explicitly ruled out job cuts and pipeline changes for now. The caveat: no such commitment covers the period after March 2027, when Plenge departs fully.

The numbers in the background tell their own story. BMS's R&D groups employed roughly 8,000 people in 2023, according to Fierce Biotech. Company-wide headcount fell from 34,100 at the close of 2023 to 32,500 at the close of 2025 — a decline of 1,600 positions over two years that the restructuring announcement does not mention.

A reversal of the post-Celgene model

The merger undoes the organizational model BMS installed after its 2019 acquisition of Celgene, according to Fierce Biotech. Before that deal, Thomas Lynch ran R&D as chief scientific officer. Afterward, the company split the function: Rupert Vessey oversaw research and early development, while Samit Hirawat oversaw global drug development. Massacesi's appointment collapses that split back into a single chain of command.

BMS is not pioneering the unified model. Eli Lilly, Merck and Pfizer already run research and development together under a single divisional head, according to Fierce Biotech. BMS is, in effect, catching up to a structure its largest peers adopted years ago.

The move also extends an operating overhaul Boerner has discussed publicly. During BMS's third-quarter earnings call, held near the end of last month, he told analysts the company is "continuing to rewire how we operate" so it can work more quickly and efficiently in R&D. Thursday's announcement gives that phrase an organizational name and a date.

For investors and employees, the practical question is execution. A single R&D head can speed decisions — or add a bottleneck where two leaders once ran parallel pipelines. The company will not show which outcome materializes until well after January 1, 2027.